These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 39337621)

  • 21. Targeting of NAD metabolism in pancreatic cancer cells: potential novel therapy for pancreatic tumors.
    Chini CC; Guerrico AM; Nin V; Camacho-Pereira J; Escande C; Barbosa MT; Chini EN
    Clin Cancer Res; 2014 Jan; 20(1):120-30. PubMed ID: 24025713
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PAK4 and NAMPT as Novel Therapeutic Targets in Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, and Mantle Cell Lymphoma.
    Khan HY; Uddin MH; Balasubramanian SK; Sulaiman N; Iqbal M; Chaker M; Aboukameel A; Li Y; Senapedis W; Baloglu E; Mohammad RM; Zonder J; Azmi AS
    Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008323
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of NAMPT aggravates high fat diet-induced hepatic steatosis in mice through regulating Sirt1/AMPKα/SREBP1 signaling pathway.
    Wang LF; Wang XN; Huang CC; Hu L; Xiao YF; Guan XH; Qian YS; Deng KY; Xin HB
    Lipids Health Dis; 2017 Apr; 16(1):82. PubMed ID: 28449683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma.
    Aboukameel A; Muqbil I; Senapedis W; Baloglu E; Landesman Y; Shacham S; Kauffman M; Philip PA; Mohammad RM; Azmi AS
    Mol Cancer Ther; 2017 Jan; 16(1):76-87. PubMed ID: 28062705
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the nicotinamide adenine dinucleotide (NAD) salvage pathway, to target glioma heterogeneity through mitochondrial oxidative stress.
    Sharma P; Xu J; Williams K; Easley M; Elder JB; Lonser R; Lang FF; Lapalombella R; Sampath D; Puduvalli VK
    Neuro Oncol; 2022 Feb; 24(2):229-244. PubMed ID: 34260721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications.
    Tan B; Young DA; Lu ZH; Wang T; Meier TI; Shepard RL; Roth K; Zhai Y; Huss K; Kuo MS; Gillig J; Parthasarathy S; Burkholder TP; Smith MC; Geeganage S; Zhao G
    J Biol Chem; 2013 Feb; 288(5):3500-11. PubMed ID: 23239881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oleate ameliorates palmitate-induced reduction of NAMPT activity and NAD levels in primary human hepatocytes and hepatocarcinoma cells.
    Penke M; Schuster S; Gorski T; Gebhardt R; Kiess W; Garten A
    Lipids Health Dis; 2017 Oct; 16(1):191. PubMed ID: 28974242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nicotinamide phosphoribosyl transferase regulates cell growth via the Sirt1/P53 signaling pathway and is a prognosis marker in colorectal cancer.
    Pan JH; Zhou H; Zhu SB; Huang JL; Zhao XX; Ding H; Qin L; Pan YL
    J Cell Physiol; 2019 Apr; 234(4):4385-4395. PubMed ID: 30191976
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-proliferation effect of APO866 on C6 glioblastoma cells by inhibiting nicotinamide phosphoribosyltransferase.
    Zhang LY; Liu LY; Qie LL; Ling KN; Xu LH; Wang F; Fang SH; Lu YB; Hu H; Wei EQ; Zhang WP
    Eur J Pharmacol; 2012 Jan; 674(2-3):163-70. PubMed ID: 22119381
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of nicotinamide phosphoribosyltransferase and depletion of nicotinamide adenine dinucleotide contribute to arsenic trioxide suppression of oral squamous cell carcinoma.
    Wang XY; Wang JZ; Gao L; Zhang FY; Wang Q; Liu KJ; Xiang B
    Toxicol Appl Pharmacol; 2017 Sep; 331():54-61. PubMed ID: 28501332
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status.
    Cea M; Cagnetta A; Acharya C; Acharya P; Tai YT; Yang C; Lovera D; Soncini D; Miglino M; Fraternali-Orcioni G; Mastracci L; Nencioni A; Montecucco F; Monacelli F; Ballestrero A; Hideshima T; Chauhan D; Gobbi M; Lemoli RM; Munshi N; Treon SP; Anderson KC
    Clin Cancer Res; 2016 Dec; 22(24):6099-6109. PubMed ID: 27287071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase.
    Olesen UH; Petersen JG; Garten A; Kiess W; Yoshino J; Imai S; Christensen MK; Fristrup P; Thougaard AV; Björkling F; Jensen PB; Nielsen SJ; Sehested M
    BMC Cancer; 2010 Dec; 10():677. PubMed ID: 21144000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells.
    Mutz CN; Schwentner R; Aryee DNT; Bouchard EDJ; Mejia EM; Hatch GM; Kauer MO; Katschnig AM; Ban J; Garten A; Alonso J; Banerji V; Kovar H
    Oncotarget; 2017 Apr; 8(15):24679-24693. PubMed ID: 28160567
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nicotinamide phosphoribosyltransferase: a potent therapeutic target in non-small cell lung cancer with epidermal growth factor receptor-gene mutation.
    Okumura S; Sasaki T; Minami Y; Ohsaki Y
    J Thorac Oncol; 2012 Jan; 7(1):49-56. PubMed ID: 22089115
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Divergent metabolic responses dictate vulnerability to NAMPT inhibition in ovarian cancer.
    Kudo K; Nomura M; Sakamoto Y; Ito S; Morita M; Kawai M; Yamashita Y; Ito K; Yamada H; Shima H; Yaegashi N; Tanuma N
    FEBS Lett; 2020 May; 594(9):1379-1388. PubMed ID: 31950503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. LCH-7749944, a novel and potent p21-activated kinase 4 inhibitor, suppresses proliferation and invasion in human gastric cancer cells.
    Zhang J; Wang J; Guo Q; Wang Y; Zhou Y; Peng H; Cheng M; Zhao D; Li F
    Cancer Lett; 2012 Apr; 317(1):24-32. PubMed ID: 22085492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.
    Cea M; Cagnetta A; Fulciniti M; Tai YT; Hideshima T; Chauhan D; Roccaro A; Sacco A; Calimeri T; Cottini F; Jakubikova J; Kong SY; Patrone F; Nencioni A; Gobbi M; Richardson P; Munshi N; Anderson KC
    Blood; 2012 Oct; 120(17):3519-29. PubMed ID: 22955917
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Restoring NAD
    Katayoshi T; Nakajo T; Tsuji-Naito K
    J Photochem Photobiol B; 2021 Aug; 221():112238. PubMed ID: 34130091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells.
    Bajrami I; Kigozi A; Van Weverwijk A; Brough R; Frankum J; Lord CJ; Ashworth A
    EMBO Mol Med; 2012 Oct; 4(10):1087-96. PubMed ID: 22933245
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nicotinamide phosphoribosyltransferase can affect metastatic activity and cell adhesive functions by regulating integrins in breast cancer.
    Santidrian AF; LeBoeuf SE; Wold ED; Ritland M; Forsyth JS; Felding BH
    DNA Repair (Amst); 2014 Nov; 23():79-87. PubMed ID: 25263164
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.